Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding

Expert Review of Proteomics

Volumn 7, Issue 4, 2010, Pages 579-589

  Ho, Lap ^a   Pasinetti, Giulio Maria ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

amyloid; Alzheimers disease; grape seed polyphenolic extract; Huntingtons disease; neurodegenerative disorders; Parkinsons disease; polyphenols; tau; tauopathy

Indexed keywords

AMYLOID BETA PROTEIN; CATECHIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GRAPE SEED EXTRACT; HUNTINGTIN; MEGANATURAL AZ; NUTRACEUTICAL; POLYPHENOL; PROANTHOCYANIDIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PHYLOGENY; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN STABILITY; REVIEW; TAUOPATHY;

ANIMALS; FLAVONOIDS; GRAPE SEED EXTRACT; HUMANS; NEURODEGENERATIVE DISEASES; PHENOLS; POLYPHENOLS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

ANIMALIA; VITACEAE;

EID: 77954968915     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.69     Document Type: Review

References (46)

1. Dimakopoulos AC. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr. Alz. Res. 2, 19-28 (2005).
2. Li X, Li H, Li XJ. Intracellular degradation of misfoded proteins in polyglutamine neurodegenerative diseases. Brain Res. Rev. 59(1), 245-252 (2008).
3. Outeiro TF, Tetzlaff J. Mechanisms of disease II: cellular protein quality control. Semin. Pediatr. Neurol. 14(1), 15-25 (2007).
4. Giannakopoulos P, Kovari E, Gold G, von Gunter A, Hof PR, Bouras C. Pathological substrates of cognitive decline in Alzheimer's disease. Front. Neurol. Neurosci. 24, 20-29 (2009).
5. Guillozet-Bongaarts AL, Glajch KE, Libson EG et al. Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathol. 113, 513-520 (2007).
6. Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 26, 457-470 (2006).
7. Roodveldt C, Christodoulou J, Dobson CM. Immunological features of a-synuclein in Parkinson's disease. J. Cell. Mol. Med. 12(5B), 1820-1829 (2008).
8. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr. Opin. Neurol. 21, 497-503 (2008).
9. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet. J. Rare Dis. 4, 3-25 (2009).
10. Bucciantini M, Calloni G, Chiti F et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. 279(30), 31374-31382 (2004).
11. Stefani M. Protein folding and misfolding on surfaces. Int. J. Mol. Sci. 9, 2515-2542 (2008).
12. Lee SJ. a-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease? Antioxid. Redox Signal. 5, 337-348 (2003).
13. Pickhardt M, Gazova Z, von Bergen M et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cell. J. Biol. Chem. 280, 3628-3635 (2005).
14. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1-6 (2007).
15. Ono K, Condron MM, Ho L et al. Effects of grape seed-derived polyphenols on amyloid b-protein self-assembly and cytotoxicity. J. Biol. Chem. 283, 321-387 (2008).
16. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. Potent anti-amyloidgenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87(1), 172-181 (2003).
17. Taniguchi S, Suzuki N, Masuda M et al. Inhibition of heparin-induced tau filament formation by phenothizaines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623 (2005).
18. Wang J, Ho L, Zhao W et al. Grape-derived polyphenolics prevent Ab oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 28, 6388-6392 (2008).
19. Ehrnhoefer DE, Duennwald M, Markovic P et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum. Mol. Genet. 15(18), 2743-2751 (2006).
20. Guo JP, Yu S, McGeer PL. Simple in vitro assays to identify amyloid-b aggregation blockers for Alzheimer's disease therapy. J. Alzheimers Dis. 19(4), 1359-1370 (2010).
21. Ho L, Yemul S, Wang J, Pasinetti GM. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J. Alzheimers Dis. 16, 433-439, (2009).
22. Ono K, Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for a synuclein fibrils in vitro. J. Neurochem. 97, 105-115 (2006).
23. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of a-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279(26), 26846-26857 (2004). (Pubitemid 38812518)
24. Yamaguchi Y, Masuda M, Sasakawa H et al. Characterization of inhibitor-bound a-synuclein dimer: role of a-synuclein N-terminal region in dimerization and inhibitor binding. J. Mol. Biol. 395(3), 445-456 (2010).
25. Masuda M, Hasegawa M, Nonaka T et al. Inhibition of a-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies. FEBS Lett. 583(4), 787-791 (2009).
26. Ehrnhoefer DE, Bieschke J, Boeddrich A et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566 (2008).
27. Rezai-Zadeh K, Shytle D, Sun N et al. Green tea epigallocatechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814 (2005).
28. Rezai-Zadeh K, Arendash GW, Hou H et al. Green tea epigallocatechin-3- gallate (EGCG) reduces b-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 1214, 177-187 (2008).
29. Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA. Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis MPTP-induced Parkinsonism. Neurodegener. Dis. 7(4), 219-231 (2010).
30. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MB. Simultaneous manipulation of multiple brain targets by green tea catchins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 14(4), 352-362 (2008).
31. Ferruzzi MG, Lobo JK, Janle EM et al. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J. Alzheimers Dis. 18(1), 113-124 (2009).
32. Sivaprakasapillai B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of grape seed extract on blood pressure in subjects with the metabolic syndrome. Metabolism 58(12), 1743-1746 (2009).
33. Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food Chem. Toxicol. 40(12), 1731-1743 (2002).
34. Wang YJ, Thomas P, Zhong JH et al. Consumption of grape seed extract prevents amyloid-b deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. Neurotox. Res. 15(1), 3-14 (2009).
35. D'Souza L, Schellenberg GD. Regulation of tau isoform expression and dementia. Biochim. Biophys. Acta 1739, 140-1115 (2005).
36. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121-1159 (2001).
37. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130 (2000).
38. Drewes G. MARKing tau for tangles and toxicity. Trends Biochem. Sci. 29, 548-555 (2004).
39. Barghorn S, Mandelkow E. Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896 (2002).
40. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA. Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-b structure. Proc. Natl Acad. Sci. USA 100, 9034-9038 (2003).
41. Mangiarini L, Sathasivam K, Seller M et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506 (1996).
42. Goux WJ, Kopplin L, Nguyen AD et al. The formation of straight and twisted filaments from short tau peptides. J. Biol. Chem. 279(26), 26868-26875 (2004).
43. Lewis J, Dickson DW, Lin WL et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487-1491 (2001).
44. Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. IRAR J. 48, 356-373 (2007).
45. Apostol BL, Illes K, Pallos J et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 15, 273-285 (2006).
46. Dose conversions across species www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm078932.pdf